0001209191-19-018091.txt : 20190308 0001209191-19-018091.hdr.sgml : 20190308 20190308161700 ACCESSION NUMBER: 0001209191-19-018091 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190306 FILED AS OF DATE: 20190308 DATE AS OF CHANGE: 20190308 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PASSERI DANIEL R CENTRAL INDEX KEY: 0001190121 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38327 FILM NUMBER: 19669288 MAIL ADDRESS: STREET 1: C/O CURIS INC STREET 2: 4 MAGUIRE ROAD CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cue Biopharma, Inc. CENTRAL INDEX KEY: 0001645460 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473324577 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 21 ERIE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-949-2680 MAIL ADDRESS: STREET 1: 21 ERIE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Imagen Biopharma, Inc. DATE OF NAME CHANGE: 20150617 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-03-06 0 0001645460 Cue Biopharma, Inc. CUE 0001190121 PASSERI DANIEL R 21 ERIE STREET CAMBRIDGE MA 02139 1 1 0 0 CEO and President Common Stock 47600 D Stock Option (right to buy) 6.42 2019-03-06 4 A 0 125000 0.00 A 2029-03-06 Common Stock 125000 125000 D Stock Option (right to buy) 11.54 2019-03-06 4 A 0 100000 0.00 A 2025-07-23 Common Stock 100000 100000 D This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 6, 2019. Represents a stock option award granted on July 23, 2018 that partially vested upon the achievement of certain performance based conditions as determined by the Compensation Committee of Cue Biopharma, Inc. on March 6, 2019. As of March 6, 2019, 50,000 of these options were vested and exercisable. The remaining 50,000 will become vested and exercisable only upon the achievement of certain performance based conditions. /s/ Daniel Passeri by Mark Busch, as attorney-in-fact 2019-03-08